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Alanine aminotransferase (ALT) levels reflect skeletal muscle volume and general performance, which 
are associated with chronic obstructive pulmonary disease (COPD) development and prognosis. 
This study aimed to investigate ALT levels as a risk factor for COPD development. This 13-year 
population-based retrospective observational cohort study included 422,452 participants for analysis. 
We classified groups according to the baseline ALT levels (groups 1–5: ALT (IU/L) < 10; 10–19; 20–29; 
30–39; and ≥ 40, respectively). The incidence of COPD was the highest in group 1, decreasing as the 
group number increased in males, but not in females. The Cox regression analysis in males revealed 
that a lower ALT level, as a continuous variable, was a significant risk factor for COPD development 
[univariable, hazard ratio (HR): 0.992, 95% confidence interval (CI): 0.991–0.994; multivariable, HR: 
0.998, 95% CI: 0.996–0.999]. In addition, COPD was more likely to develop in the lower ALT level 
groups (groups 1–4; < 40 IU/L), than in the highest ALT level group (group 5; ≥ 40 IU/L) (univariable, HR: 
1.341, 95% CI: 1.263–1.424; multivariable, HR: 1.097, 95% CI: 1.030–1.168). Our findings suggest that 
males with low ALT levels should be carefully monitored for COPD development.
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Chronic obstructive pulmonary disease (COPD) is a chronic airway disease requiring life-long management. 
COPD has contributed to an enormous socioeconomic burden  worldwide1. Early detection of COPD can lead 
to appropriately timed treatment, prevention of airway remodeling in early stages, and improvements in the 
symptoms and prognosis of  COPD2,3. Determining risk factors predicting COPD development aids in the early 
detection of COPD. To date, we know that heavy smoking history, old age, male sex, and other epidemiologic 
factors contribute to COPD  development4,5.
Alanine aminotransferase (ALT) levels can be easily measured from the serum and are commonly used to 
evaluate liver  disease6. However, recent studies have revealed that low ALT levels predict poor health outcomes, 
including death, and reflect skeletal muscle volume; these are important factors representing the general condi-
tion and performance in old  age7–13. In particular, decreased skeletal muscle volume is an important risk factor 
for COPD  development14,15. Therefore, low ALT levels might adversely affect COPD development. Moreover, 
recent studies have revealed that liver diseases, such as non-alcoholic fatty liver disease, affect COPD develop-
ment and prognosis. Therefore, high ALT levels might also adversely affect  COPD16–18.
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This study aimed to investigate the role of serum ALT levels in predicting COPD development, using a large, 
nationwide, population-based cohort database.
Results
Baseline clinical characteristics. The 422,452 participants were divided into five groups based on the 
serum ALT level at the time of the health check-up. The baseline characteristics of each group are described in 
Table 1. Most variables were associated with the ALT group. The proportion of females was higher in groups 1 
and 2 (76.7% and 62.2%, respectively) and lower in groups 3, 4, and 5 (39.7%, 27.6%, and 21.7%, respectively; 
P < 0.0001). Smoking status was also significantly different according to the ALT group. The proportion of cur-
rent smokers was higher in group 5 (34.2%) than in groups 1 (11.9%) and 2 (17.4%) (P < 0.0001). The percentage 
of participants who did not exercise was higher in group 1 (59.4%) than in the other groups, especially group 5 
(51.7%) (P < 0.001). Participants in group 1 were younger and had a lower body mass index (BMI), blood pres-
sure, hemoglobin level, fasting glucose level, and total cholesterol level than those in other groups (P < 0.0001).
ALT level and incidence of COPD development. The prevalence of newly developed COPD in the 
study population over the 13-year period was 3.5% (n = 14,656). Comparing the five groups according to the 
serum ALT level, the prevalence of newly developed COPD was 2.8%, 3.3%, 3.8%, 3.7%, and 3.1%, respectively 
(P < 0.0001; Fig. 1A). There was also no consistent correlation between the ALT group and COPD development 
in the cumulative incidence (Fig. 1C).
We conducted a subgroup analysis according to sex and smoking status. In male participants, COPD develop-
ment was the most prevalent in group 1, decreasing as the group number increased (4.2%, 4.2%, 3.9%, 3.5%, and 
2.9%, respectively; P < 0.0001). Conversely, in female participants, COPD development was the most prevalent 
in group 4, decreasing as the group number decreased, except for group 5 (2.3% in group 1, 2.8% in group 2, 
3.7% in group 3, 4.1% in group 4, and 3.7% in group 5; P < 0.0001). On comparing the cumulative incidence 
of COPD, the steepness of the slopes of the Kaplan–Meier curves in male participants increased as the group 
number decreased; however, these values were not sequential in female participants (Fig. 1D,E).
Table 1.  Baseline characteristics of participants according to the serum ALT levels. ALT alanine 
aminotransferase, AST aspartate transaminase, BMI body mass index, CCI Charlson’s comorbidity index, ɤGT 
gamma-glutamyl transferase.
Overall Group 1 Group 2 Group 3 Group 4 Group 5 P-value
Number of participants, n (%) 422,452 12,169 (2.9) 168,765 (39.9) 128,723 (30.5) 57,700 (13.7) 55,095 (13.0)
Categorical variables, n (%)
Sex
Male 229,095 (54.2) 2,834 (23.3) 63,741 (37.8) 77,648 (60.3) 41,751 (72.4) 43,121 (78.3)
 < 0.0001
Female 193,357 (45.8) 9,335 (76.7) 105,024 (62.2) 51,075 (39.7) 15,949 (27.6) 11,974 (21.7)
Smoking status
Never smoker 268,746 (63.6) 9,725 (79.9) 122,729 (72.7) 78,430 (60.9) 30,920 (53.6) 26,942 (48.9)
 < 0.0001
Ex-smoker 35,876 (8.5) 464 (3.8) 9,821 (5.8) 12,138 (9.5) 6,582 (11.4) 6,871 (12.5)
Current 
smoker 99,825 (23.6) 1,449 (11.9) 29,285 (17.4) 32,726 (25.4) 17,533 (30.4) 18,832 (34.2)
Unknown 18,005 (4.3) 531 (4.4) 6,930 (4.1) 5,429 (4.2) 2,665 (4.6) 2,450 (4.4)
Physical activ-
ity (number of 
times/week)
0/week 227,939 (54.0) 7,236 (59.4) 95,223 (56.4) 67,694 (52.6) 29,321 (50.8) 28,465 (51.7)
 < 0.0001
1–2/week 104,312 (24.7) 2,542 (20.9) 38,011 (22.5) 32,153 (25.0) 15,847 (27.5) 15,759 (28.6)
3–4/week 40,511 (9.6) 1,082 (8.9) 15,700 (9.3) 12,916 (10.0) 5,780 (10.0) 5,033 (9.1)
5–6/week 11,144 (2.6) 276 (2.3) 4,572 (2.7) 3,606 (2.8) 1,448 (2.5) 1,242 (2.3)
Almost every 
day 25,817 (6.1) 639 (5.3) 10,303 (6.1) 8,551 (6.6) 3,450 (6.0) 2,874(5.2)
Unknown 12,729 (3.0) 394 (3.2) 4,956 (3.0) 3,803 (3.0) 1,854 (3.2) 1,722 (3.1)
Continuous variables, mean ± standard deviation
Age 49.7 ± 7.1 47.7 ± 6.7 49.6 ± 7.1 50.4 ± 7.1 49.9 ± 7.0 49.0 ± 6.8  < 0.0001
Comorbidities CCI score 0.4 ± 0.7 0.3 ± 0.7 0.4 ± 0.7 0.4 ± 0.7 0.4 ± 0.8 0.4 ± 0.8  < 0.0001
BMI (kg/m2) 24.1 ± 2.9 22.7 ± 2.7 23.3 ± 2.8 24.2 ± 2.8 24.8 ± 2.8 25.4 ± 3.0  < 0.0001
Systolic blood pressure 
(mmHg) 125.8 ± 17.7 120.2 ± 17.1 123.1 ± 17.3 126.8 ± 17.6 128.7 ± 17.5 130.1 ± 17.4  < 0.0001
Diastolic blood pressure 
(mmHg) 79.4 ± 11.7 75.6 ± 11.4 77.4 ± 11.5 80.0 ± 11.6 81.5 ± 11.6 82.5 ± 11.6  < 0.0001
Hemoglobin (g/dL) 14.0 ± 1.5 12.9 ± 1.6 13.5 ± 1.5 14.1 ± 1.4 14.5 ± 1.4 14.7 ± 1.4  < 0.0001
Fasting blood glucose (mg/dL) 97.4 ± 33.7 91.7 ± 28.5 94.1 ± 30.7 97.9 ± 34.1 100.6 ± 36.2 104.4 ± 38.2  < 0.0001
Total cholesterol (mg/dL) 200.3 ± 38.3 187.5 ± 37.0 195.2 ± 36.3 202.1 ± 37.6 205.9 ± 39.2 208.6 ± 41.9  < 0.0001
Liver function 
test
AST (IU/L) 26.6 ± 17.1 17.9 ± 19.8 20.6 ± 6.0 25.2 ± 7.5 30.0 ± 10.5 46.2 ± 35.5  < 0.0001
ALT (IU/L) 26.2 ± 21.3 7.8 ± 1.4 15.0 ± 2.7 23.9 ± 2.8 33.7 ± 2.8 61.8 ± 40.3  < 0.0001
ɤGT (IU/L) 36.9 ± 49.9 16.0 ± 15.1 21.1 ± 17.1 33.5 ± 30.9 48.8 ± 46.5 85.1 ± 101.5  < 0.0001
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Figure 1.  Prevalence and incidence of COPD development over 13 years. Prevalence of COPD development 
over 13 years according to sex (A) and smoking status (B). Kaplan–Meier curves for the cumulative incidence 
of COPD development over 13 years according to the ALT group in all participants (C), males (D), females (E), 
never smokers (F), ex-smokers (G), and current smokers (H). ALT alanine aminotransferase, COPD chronic 
obstructive pulmonary disease. Adobe Illustrator version Creative Cloud was used to arrange the graphs and to 
add legends. (http:// www. adobe. com/ au/ produ cts/ illus trator. html).
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Among the subgroups divided according to smoking status, a negative correlation with COPD prevalence was 
only observed in the current smoker subgroup (5.4% in group 1, 5.0% in group 2, 4.5% in group 3, 3.9% in group 
4, and 3.3% in group 5; P < 0.0001). In the other subgroups (never smokers and ex-smokers), the results were 
similar to the patterns observed in female participants (Fig. 1B). The steepness of the slopes of the Kaplan–Meier 
curves for cumulative COPD development in current smokers increased as the group number decreased; how-
ever, these values were not sequential in the other subgroups (Fig. 1F–H).
ALT level as a risk factor for COPD development. The univariable and multivariable Cox regression 
analyses revealed that old age, male sex, smoking, comorbidities, lack of exercise, low systolic blood pressure, 
and lower ALT levels were significant risk factors for COPD development [hazard ratio (HR): 0.998, 95% con-
fidence interval (CI): 0.997–0.999, P < 0.0001; Supplementary Table  1]. To assess whether the ALT level was 
related to other variables that are already well-established risk factors for COPD development, correlation coef-
ficients between each variable were analyzed and drawn as a graph (Supplementary Fig. 1A). ALT showed a 
strong association with other liver function tests (aspartate aminotransferase [AST], gamma-glutamyl trans-
ferase [ɤGT]); however, it did not show an apparent association with other risk factors for COPD development 
at baseline. Male sex was highly associated with current smoking; therefore, subgroup analysis was conducted 
according to sex and smoking status to assess the specific factors that more strongly explained the association 
between low ALT and COPD.
In males, lower ALT level was a significant risk factor for COPD development according to the multivari-
able Cox regression analysis (HR: 0.998, 95% CI: 0.996–0.999, P = 0.0001; Table 2). However, in females, the 
ALT level was not a significant risk factor for COPD development (HR: 1.000, 95% CI: 0.999–1.002, P = 0.8068; 
Supplementary Table 2). In both males and females, the correlation coefficients between each variable were also 
analyzed to identify the link between the ALT level and other risk factors for COPD. The ALT level did not show 
an apparent association with other risk factors for COPD development (Supplementary Fig. 1B,C).
A subgroup analysis according to smoking status revealed a similar pattern. In the current smoker subgroup, 
lower ALT level was a significant risk factor for COPD development (HR: 0.996, 95% CI: 0.994–0.998, P = 0.0002; 
Supplementary Table 3). However, the ALT level was not a significant risk factor in never smokers (HR: 1.000, 
95% CI: 0.998–1.001, P = 0.4678; Supplementary Table 4).
Spline curves between ALT and the HR for COPD development were compared according to smoking status 
in each sex group (Fig. 2). As with the previous results, in all participants and females, the curves did not show 
a consistent correlation between the ALT levels and the HR for COPD development (Fig. 2A,C, respectively). 
By contrast, the curves in males showed a negative correlation between ALT and the HR of COPD development 
(Fig. 2B).
In the current smoker subgroup, the curves of all and male current smokers showed a negative correlation 
between ALT and the HR of COPD development (Fig. 2D,E, respectively); by contrast, the curves of female 
current smokers did not show a consistent correlation (Fig. 2F). In never smokers, only the curve of male never 
Table 2.  Cox regression analyses for COPD development in males. ALT alanine aminotransferase, AST 
aspartate aminotransferase, BMI body mass index, CCI Charlson’s comorbidity index, CI confidence interval, 
COPD chronic obstructive pulmonary disease, HR hazard ratio, ɤGT gamma-glutamyl transferase.
Variable
Univariable analysis Multivariable analysis
HR 95% CI P-value HR 95% CI P-value
Smoking (never smoker vs.)
Ex-smoker 0.934 0.872–1.001 0.0549 1.117 1.041–1.199 0.0022
Current smoker 1.275 1.216–1.336  < 0.0001 1.539 1.465–1.617  < 0.0001
Physical activity (0/week vs.)
1–2/week 0.652 0.619–0.686  < 0.0001 0.772 0.732–0.814  < 0.0001
3–4/week 0.590 0.544–0.640  < 0.0001 0.675 0.621–0.734  < 0.0001
5–6/week 0.708 0.615–0.814  < 0.0001 0.763 0.662–0.880 0.0002
Almost every day 1.021 0.939–1.112 0.6234 0.852 0.781–0.929 0.0003
Age 1.101 1.097–1.104  < 0.0001 1.099 1.095–1.102  < 0.0001
Comorbidities (CCI score) 1.274 1.248–1.300  < 0.0001 1.203 1.177–1.231  < 0.0001
BMI (kg/m2) 0.934 0.926–0.941  < 0.0001 0.964 0.956–0.972  < 0.0001
Systolic blood pressure (mmHg) 1.001 1.000–1.002 0.1457
Diastolic blood pressure (mmHg) 0.995 0.993–0.997  < 0.0001 0.994 0.992–0.996  < 0.0001
Hemoglobin (g/dL) 0.907 0.890–0.924  < 0.0001 1.013 0.993–1.033 0.2164
Fasting blood glucose (mg/dL) 0.999 0.998–1.000 0.0111 0.998 0.997–0.999  < 0.0001
Total cholesterol (mg/dL) 0.998 0.997–0.999  < 0.0001 0.999 0.999–1.000 0.0093
AST (IU/L) 0.999 0.998–1.001 0.3200
ALT (IU/L) 0.992 0.991–0.994  < 0.0001 0.998 0.996–0.999 0.0001
ɤGT (IU/L) 1.000 0.999–1.000 0.1404
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smokers showed a negative correlation; the other subgroups did not show a consistent correlation (Fig. 2G–I, 
respectively). The results suggest that ALT is a significant risk factor in males rather than in current smokers.
In males, we redefined groups 1–4 and group 5 as low and high ALT groups, respectively. Comparisons 
between these two groups are described in Supplementary Table 5. As with the baseline characteristics of all 
participants, most variables were associated with the ALT group.
Additional analyses showed that in males, low ALT level was a significant risk factor for COPD development 
on both univariable (HR: 1.341, 95% CI: 1.263–1.424, P < 0.0001) and multivariable Cox regression (HR: 1.097, 
95% CI: 1.030–1.168, P = 0.0042) analyses (Fig. 3). The Kaplan–Meier curves for the cumulative COPD develop-
ment in the two groups also showed a significant difference. In the low ALT group, the cumulative incidence of 
COPD was higher than that in the high ALT group (3.9% vs. 2.9%, P < 0.0001, Fig. 4).
Discussion
To our knowledge, this is the first study to find that a lower serum ALT level is a risk factor for COPD develop-
ment in males. We believe that ALT levels reflect the overall health status, as described  previously10. Therefore, 
the HR of the ALT level became weaker after adjusting for other risk factors. However, low ALT level remained 
an independent risk factor for COPD development after adjusting for other factors.
Figure 2.  Spline curves of the hazard ratio for COPD development. Spline curves are shown for all participants 
(A), males (B), females (C), all current smokers (D), male current smokers (E), female current smokers (F), all 
never smokers (G), male never smokers (H), and female never smokers (I). ALT alanine aminotransferase, CI 
confidence interval, COPD chronic obstructive pulmonary disease. Adobe Illustrator version Creative Cloud 
was used to arrange the graphs and to add legends (http:// www. adobe. com/ au/ produ cts/ illus trator. html).
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We also observed that the effects of ALT level on COPD development differed according to sex. Previous 
studies have described the association between ALT levels and obesity. Fat accumulation accelerates the chrono-
logical aging of liver cells, increasing the vulnerability of the liver cells to oxidative stress and energy metabolic 
pressure, thus increasing liver enzyme  levels19–21. However, this process can differ in males and  females22,23. Since 
sex hormones affect fat and muscle distributions, the subcutaneous fat storage capacity is lower in males than in 
females. Therefore, in males, fat accumulates more in other tissues, including the viscera and liver, rather than 
in subcutaneous tissue, which may lead to greater fat accumulation in the liver in the early stages of obesity. As 
a result, serum ALT levels may be elevated even in the early stages of  obesity21,24–27. Therefore, the ALT level in 
males may have a stronger relationship with fat accumulation associated with general nutrition, performance 
scales, and health status compared to that in females. This might explain why the effects of ALT level on COPD 
development are more substantial in males than in females. However, further studies are needed to establish the 
exact relationship between the ALT level and COPD.
The effects of the ALT level on COPD development were more prominent in male current smokers than in 
male never smokers. The relationship between smoking status and ALT level is also unclear. Breitling et al.28 
implied a trend towards a significant negative association between smoking intensity and serum ALT levels in 
non-drinkers in a cross-sectional study. Most other studies have also observed an inverse association or the lack 
of an association between smoking and ALT  levels28–31. However, it is known that males and current smokers 
are more susceptible to developing COPD. We surmise that the effect of the ALT level on COPD development 
in male current smokers was accentuated in these vulnerable subgroups.
According to a recent literature review, COPD is underdiagnosed in 65–80% of participants with chronic 
airflow  limitations32. To control the disease effectively, the early diagnosis and treatment of COPD are vital for 
preventing airway remodeling in the early  stages2,3. Additionally, the ALT level is a commonly performed test 
that is inexpensive, easy to obtain from serum, and included in most basic chemical tests. Therefore, this study 
suggests the careful monitoring of males with low ALT levels, which may be helpful in the early detection of 
COPD and improved COPD prognosis in these individuals. Furthermore, Lasman et al. reported that low ALT 
levels are associated with mortality in patients with COPD with a history of  exacerbation33. Therefore, the careful 
monitoring of patients with COPD with low ALT levels may also help predict the prognosis.
Our study had several limitations. First, we divided the participants into five groups based on ALT intervals 
of 10 IU/L, in alignment with previous studies, because there are no reference cut-off values for low ALT  levels12. 
Second, the diagnosis of COPD in our study was based on International Classification of Disease, 10th edition 
Figure 3.  Hazard ratios for COPD development in males. AST aspartate aminotransferase, ALT alanine 
aminotransferase, BMI body mass index, CCI Charlson’s comorbidity index, COPD chronic obstructive 
pulmonary disease, ɤGT gamma-glutamyl transferase.
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(ICD-10) codes and prescribed medication data from the Korean National Health Insurance Service (NHIS) 
database, without pulmonary function testing. Similarly, we also defined liver disease based on ICD-10 codes. 
Despite these limitations, our study had several strengths. Above all, it was the first study, to our knowledge, to 
investigate the relationship between serum ALT levels and COPD development. Moreover, it was a long-term 
cohort study, which allowed us to analyze the risk factors potentially affecting COPD development. Finally, the 
results had high statistical power owing to the large-scale analysis involving 422,452 participants.
Conclusions
The current results suggest that low serum ALT levels may play a significant role in COPD development in 
males. Therefore, clinicians should carefully monitor male patients with low ALT levels for COPD development.
Methods
Study design and population. This retrospective cohort study was conducted in a health check-up cohort 
population from the Korean NHIS database. In South Korea, populations aged 40–79 years participated in the 
biennial national health screening program covered by the Korean National Health Insurance cooperation. This 
cohort group is a simple random sample representing 10% of the 5.15 million populations who participated in 
the national health screening program from 2002 to 2003.
Among the 514,844 participants, 73,404 participants aged above 65 years were excluded to reduce the con-
founding effects of extreme old age on the development of COPD; 3857 were excluded owing to a diagnosis of 
COPD at the time of the health check-up; and 15,131 were excluded due to diagnoses of liver disease such as viral 
liver disease, non-alcoholic fatty liver disease, and hepatocellular carcinoma at the time of the health check-up, 
to limit the confounding effects of liver disease on ALT levels. Finally, 422,452 participants were included in the 
analysis (Fig. 5).
Participants were divided into five groups, based on serum ALT levels at baseline: group 1, ALT (IU/L) < 10; 
group 2, 10 ≤ ALT < 20; group 3, 20 ≤ ALT < 30; group 4, 30 ≤ ALT < 40; and group 5, ALT ≥ 40. COPD develop-
ment was retrospectively compared among all groups for 13 years.
Parameters included in data collection. The basic demographic data included the participant’s age and 
sex, and insurance claim data included the dates of hospital visits, diagnostic codes encoded by the ICD-10, and 
prescriptions. The Charlson’s comorbidity index was calculated based on comorbidities using ICD-10  codes34. 
Health check-up data provided the results of the health check-ups conducted in 2002 or 2003 and included the 
results of BMI (kg/m2) and systolic and diastolic blood pressure (mmHg) measurements, as well as hemoglobin 
(g/dL), fasting blood glucose (mg/dL), total cholesterol (mg/dL), AST (IU/L), ALT (IU/L), and ɤGT (IU/L) lev-
els. Moreover, health check-up data included a self-report questionnaire, which the participants answered dur-
ing the health check-up, providing information regarding smoking status (never smoker, ex-smoker, and current 
smoker) and physical activity (0, 1–2, 3–4, 5–6 times/week, and almost every day).
Definition of COPD development. As the NHIS database does not include data from pulmonary func-
tion tests, we defined COPD development based on the diagnostic codes of the ICD-10 and prescriptions con-
tained in the insurance claim data, as suggested by previous  studies35–37. COPD development was determined 
when all the following criteria were met: (1) age above 40 years; (2) ICD-10 diagnostic code of COPD or emphy-
sema (J43.0x–J44.x, except J43.0, as the primary or secondary diagnosis [within the fourth position]); (3) the use 
Figure 4.  Kaplan–Meier curves of the cumulative COPD development in males. ALT alanine aminotransferase, 
COPD chronic obstructive pulmonary disease.
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of COPD medications, including a muscarinic antagonist, beta-2 agonist, inhaled corticosteroid, phosphodies-
terase-4 inhibitor, or methylxanthine; and (4) first diagnosis of COPD in the follow-up period.
Definition of liver disease. Liver diseases were defined using diagnostic codes. The following ICD-10 
codes were used in this study to exclude the effects of these underlying liver diseases on ALT levels: K70.x–K77.x, 
disease of liver; B15.x–B19.x, viral hepatitis; E83.0, Wilson disease; and C22.0, liver cell carcinoma.
Statistical analysis. To compare baseline characteristics across groups, chi-squared tests were used for 
categorical variables, and paired t-test or one-way analyses of variance with Bonferroni post-hoc tests were 
used for continuous variables. Univariable and multivariable Cox regression analyses were performed to evalu-
ate the HR of each variable for COPD development. A subgroup analysis was performed according to sex and 
smoking status. Kaplan–Meier curves were drawn to evaluate the cumulative incidence of COPD among the 
groups according to serum ALT level. P-values < 0.05 were considered to indicate statistical significance. Statisti-
cal analyses were conducted using R (version 3.3.3; R Foundation for Statistical Computing, Vienna, Austria) 
software. Furthermore, spline curves of the HR for COPD development were drawn using the pspline R package, 
and correlation coefficient plots were drawn using the corrplot R package.
Ethics approval and consent to participate. This study used NHIS-NSC data (NHIS-2019-2-183) pro-
vided by the NHIS. The study was approved by the Institutional Review Board of Gangnam Severance Hospital 
(number: 3-2019-0123). As the data from NIHS contained no personal information, the need for informed 
consent was waived. The Institutional Review Board of Gangnam Severance Hospital approved the waiver of the 
informed consent. All data were collected in accordance with the amended Declaration of Helsinki. The authors 
declare no conflict of interest with NHIS.
Data availability
The data that support the findings of this study are available from NHIS. Restrictions apply to the availability of 
these data, which were used under license for this study. Data are available at URL: https:// nhiss. nhis. or. kr with 
the permission of NHIS.
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